The CSF biomarkers for AD and MCI subjects did not available, thus we performed the innovative Simoa assay to assess Total Tau, phosphorylated in 181 Tau, Amyloid beta 40, and Amyloid beta 42 peptides in plasma samples. Here, MAPT is linked to Alzheimer disease.